Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: HLX13
DRUG: Yervoy
DRUG: OPDIVO

Sponsor

Shanghai Henlius Biotech